DelveInsight's "Cardiotoxicity Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cardiotoxicity Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cardiotoxicity market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cardiotoxicity: An Overview
Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.
Several cancer drugs and treatments can cause direct damage to the heart. These drugs can cause many cardiac issues, including heart failure, high blood pressure, low blood pressure, heart attacks, irregular heartbeat, slow heart rate, or fluid around the heart.
Cardiotoxicity Market Key Facts
-
Rosa et al. (2016) reported that late-onset chronic progressive anthracycline-induced cardiotoxicity occurs at least 1 year after completing therapy in 1.6−5% of patients though it may not become clinically evident until 10–20 years after the first dose of therapy.
-
Johnson et al. (2017) stated that immune checkpoint inhibitors (antitumor agents) ipilimumab and nivolumab lead to a range of immune-related toxicities, including myocarditis and the incidence of myocarditis in patients taking these agents was between 0.27% and 1.14%.
-
As per Curiglioano et al. (2016), in a cohort of breast cancer patients, the cumulative incidence of heart failure after 10 years of cancer treatment was 38% after anthracyclines and 32.5% with non-anthracycline chemotherapy regimens.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cardiotoxicity market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Cardiotoxicity market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Cardiotoxicity Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Cardiotoxicity Epidemiology Segmentation
-
Total Number of Cardiotoxicity Patients
-
Total Number of Patients taking Chemotherapy in Various Cancer
-
Total Incident Cases of Various Cancer (Breast Cancer, Lung Cancer, and others)
-
Total Number of Cardiotoxicity Patients taking Specific Chemotherapy Agents in the (Anthracycline, TKI and others)
Cardiotoxicity Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cardiotoxicity market or expected to get launched during the study period. The analysis covers Cardiotoxicity market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cardiotoxicity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report - https://www.delveinsight.com/sample-request/cardiotoxicity-market
Cardiotoxicity Therapeutics Analysis
The dynamics of cardiotoxicity are likely to change in the coming years due to the improvement in research underdoing to develop less cytotoxic drugs.
Some of the leading companies, such as Moleculin Biotech, Monopar Therapeutics, and others, are developing therapies having less cardiotoxicity.
Cardiotoxicity Therapies covered in the report include -
-
Annamycin
-
Camsirubicin
And many others.
Besides these, several companies are working on early detection of cardiotoxicity to prevent adverse events caused by the drugs. One such company, Myocardial Solutions, has developed MyoStrain, a rapid MRI-based heart function test that quantifies the effects of a disease, drugs, and ischemia across 48 heart segments in under 10 min.
Get More Detailed Insights Into the Emerging Therapies & Key Companies -
https://www.delveinsight.com/sample-request/cardiotoxicity-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cardiotoxicity Competitive Intelligence Analysis
4. Cardiotoxicity Market Overview at a Glance
5. Cardiotoxicity Disease Background and Overview
6. Cardiotoxicity Patient Journey
7. Cardiotoxicity Epidemiology and Patient Population
8. Cardiotoxicity Treatment Algorithm, Current Treatment, and Medical Practices
9. Cardiotoxicity Unmet Needs
10. Key Endpoints of Cardiotoxicity Treatment
11. Cardiotoxicity Marketed Products
12. Cardiotoxicity Emerging Therapies
13. Cardiotoxicity Seven Major Market Analysis
14. Attribute Analysis
15. Cardiotoxicity Market Outlook (7 major markets)
16. Cardiotoxicity Access and Reimbursement Overview
17. KOL Views on the Cardiotoxicity Market.
18. Cardiotoxicity Market Drivers
19. Cardiotoxicity Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report - https://www.delveinsight.com/sample-request/cardiotoxicity-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Psychosis Market
“Psychosis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Psychosis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
